ATE285794T1 - Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien - Google Patents

Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien

Info

Publication number
ATE285794T1
ATE285794T1 AT01928654T AT01928654T ATE285794T1 AT E285794 T1 ATE285794 T1 AT E285794T1 AT 01928654 T AT01928654 T AT 01928654T AT 01928654 T AT01928654 T AT 01928654T AT E285794 T1 ATE285794 T1 AT E285794T1
Authority
AT
Austria
Prior art keywords
agonists
joint
treatment
bone pathologies
retinoid antagonists
Prior art date
Application number
AT01928654T
Other languages
English (en)
Inventor
Maurizio Pacifici
Roshantha A Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE285794T1 publication Critical patent/ATE285794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
AT01928654T 2000-04-20 2001-04-19 Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien ATE285794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/552,823 US20030114482A1 (en) 1999-12-15 2000-04-20 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
PCT/US2001/012742 WO2001080894A2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Publications (1)

Publication Number Publication Date
ATE285794T1 true ATE285794T1 (de) 2005-01-15

Family

ID=24206947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01928654T ATE285794T1 (de) 2000-04-20 2001-04-19 Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien

Country Status (9)

Country Link
US (1) US20030114482A1 (de)
EP (1) EP1274456B1 (de)
JP (1) JP2003531180A (de)
AT (1) ATE285794T1 (de)
AU (3) AU2001255488B2 (de)
CA (1) CA2407021A1 (de)
DE (1) DE60108094T2 (de)
HK (1) HK1053053B (de)
WO (1) WO2001080894A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1701934B1 (de) * 2003-12-26 2009-02-25 Allergan, Inc. DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
JP2007070281A (ja) * 2005-09-06 2007-03-22 Matsumoto Shika Univ レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤
EP1959945B1 (de) * 2005-12-13 2014-12-03 McGill University Fenretinid zur korrektur des lipidungleichgewichts bei einer person
WO2009102789A2 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteroarthritis
EP2613776B1 (de) 2010-09-01 2020-07-29 Thomas Jefferson University Zusammensetzungen und verfahren zur muskelreparatur und -regeneration
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
EP2918290B1 (de) 2012-11-08 2020-09-02 Yamaguchi University Therapeutikum für keratokonjunktivitis
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
EP3446690A1 (de) 2013-05-22 2019-02-27 Yamaguchi University Inhibitor für retinochoroidale erkrankungen
EP4249490A3 (de) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Verfahren zur behandlung von heterotopischer ossifikation
KR20190100187A (ko) 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. 다중 골연골종(mo)을 치료하는 방법
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
EP0889032A4 (de) * 1996-03-18 2000-01-05 Eisai Co Ltd Carbonsaure derivate mit kondensierten ringen
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis

Also Published As

Publication number Publication date
DE60108094D1 (de) 2005-02-03
EP1274456A2 (de) 2003-01-15
JP2003531180A (ja) 2003-10-21
WO2001080894A3 (en) 2002-07-25
WO2001080894A2 (en) 2001-11-01
AU2001255488B2 (en) 2006-07-27
US20030114482A1 (en) 2003-06-19
CA2407021A1 (en) 2001-11-01
AU2006233216A1 (en) 2006-11-16
HK1053053A1 (en) 2003-10-10
HK1053053B (zh) 2005-06-10
EP1274456B1 (de) 2004-12-29
AU5548801A (en) 2001-11-07
DE60108094T2 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE60120372D1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
EA200300845A1 (ru) Модифицированные антитела и способы применения
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ATE460402T1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1- rezeptors
DE60108094D1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE434437T1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE421326T1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties